VYNE Therapeutics Announces Phase 1a SAD Data For VYN202, A Novel BD2-Selective BET Inhibitor; VYN202 Was Generally Well Tolerated With No Drug-Related Adverse Events

Author: Benzinga Newsdesk | September 12, 2024 08:13am

• VYN202 was generally well tolerated with no drug-related adverse events
  
   
• Pharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood
• Pharmacodynamic activity observed on target engagement and inflammatory biomarkers
• Dosing has begun in the MAD portion of the trial with results expected in Q4 2024

BRIDGEWATER, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced positive data from the single ascending dose ("SAD") portion of its ongoing Phase 1a trial of VYN202. The Phase 1a trial is a two-part, double-blind, placebo-controlled dose-escalation study in healthy volunteers consisting of SAD and multiple ascending dose ("MAD") components to evaluate the safety, tolerability, pharmacokinetics ("PK") and pharmacodynamics of VYN202. Findings from the SAD portion of the Phase 1a trial to date are as follows:

Posted In: VYNE